rTMS Treatment of Persistent Headache and Post Concussion Symptoms Attributed to Mild Traumatic Injury to the Head
追踪信息 | |||
---|---|---|---|
首次提交日期 ICMJE | September 26, 2018 | ||
首次发布日期e ICMJE | October 1, 2018 | ||
最后更新发布日期 | October 1, 2018 | ||
预计研究开始日期 ICMJE | April 15, 2017 | ||
预计主要完成日期 | September 30, 2018 (主要结果测量的最终数据收集日期) | ||
目前主要观察指标 ICMJE |
Change in headache severity from baseline to 1 month post-treatment.[ Time Frame: Repeated measures: Baseline (0-2 weeks),1 month (6-8 weeks) ] Numeric Pain Rating Scale (NPRS): a tool to assess severity of pain, which is graded from 0-10 (11 points) with 0 defined as "no pain" and 10 as "worst possible pain". Change in headache frequency from baseline to 1 month post-treatment.[ Time Frame: Repeated measures: Baseline (0-2 weeks),1 month (6-8 weeks) ] Number of headaches/2 weeks |
||
原始主要观察测量 ICMJE | 与当前相同 | ||
目前的二级观察 ICMJE |
|
||
描述性信息 | |||
简略标题 ICMJE | rTMS Treatment of Persistent Headache and Post Concussion Symptoms Attributed to Mild Traumatic Injury to the Head | ||
正式标题 ICMJE | Treatment of Persistent Headache Attributed to Mild Traumatic Injury to the Head (PHATIH) in Patients With Persistent Post Concussion Symptoms (PPCS) Using Repetitive Transcranial Magnetic Stimulation (rTMS) | ||
简要概况 | The objective of this study is to investigate the treatment effect of repetitive transcranial magnetic stimulation in patients with a history of both persistent post-traumatic headache and post-concussion symptoms. In this double-blind, sham-controlled, concealed allocation, randomized clinical trial, 20 patients aged 18-65 yrs will be recruited from the Calgary Brain Injury Program (CBIP) and the Calgary Headache Assessment and Management Program (CHAMP) / Calgary Chronic Pain Centre, Calgary, Alberta, Canada. Patients will engage in a two-week rTMS treatment protocol (10 treatments) and will be followed for 6 months after therapy. |
||
详细说明 | Demographic information will be collected two weeks prior to starting the study including age, sex, education, headache history, concussion history, past medical history, medication use, and family medical history. Headache history will be collected including frequency, severity, medication-use, type of headache, associated symptoms (i.e. neck pain, photophobia, phonophobia, nausea, vomiting) and headache triggers. Baseline questionnaires will be completed including headache intensity scale - 6 (HIT-6), Rivermead PPCS questionnaire, British Columbia post-concussion symptom inventory (BC-PSI), Montreal cognitive assessment (MoCA), quality of life after brain injury questionnaire (QOLIBRI), patient health questionnaire-9 (PHQ-9), generalized anxiety disorder scale-7 (GADS-7) and the post traumatic stress disorder checklist for DSM-5 (PCL-5). Patients will keep a two-week baseline headache diary before treatment, 2 weeks during treatment, 2 weeks following rTMS, and for 2 weeks at the 1, 3, and 6 month follow up assessments (total of 12 weeks). Patients will be reassessed at the completion of their rTMS treatment (day 14), and at 1, 3, and 6 months post-treatment. The questionnaires including: HIT-6, Rivermead PPCS questionnaire, PC-PSI, QOLIBRI, PHQ-9 and GAD-7 will be completed at all follow up visits. | ||
研究类型 ICMJE | Interventional | ||
研究阶段 | Phase 1/Phase 2 | ||
研究设计 ICMJE | 分配: Randomized 干预模型: Parallel Assignment 干预模型描述: 盲法: Interventional 盲法描述:Participants will be randomized with a random number generator to receive either sham or rTMS. Allocation will be concealed through the use of sequentially numbered, sealed, opaque envelopes. 主要目的: Treatment |
||
适用条件 ICMJE | |||
干预项目 ICMJE |
|
||
研究工具 |
|
||
招募信息 | |||
招募状态 ICMJE | Active, not recruiting | ||
预计入组 ICMJE |
20 | ||
原始预计入组 ICMJE | 与当前相同 | ||
预计研究完成日期 | January 30, 2019 | ||
预计主要完成日期 | September 30, 2018 (主要结果测量的最终数据收集日期) | ||
合格标准 ICMJE | Inclusion Criteria: - Diagnosis of a persistent headache attributed to traumatic injury to the head based on the ICHD-3 criteria - Diagnosis of persistent post-concussion symptoms based on the ICD-10 criteria - mTBI occurrence from 3 months to 5 years from study start date Exclusion Criteria: - Prior history of TMS therapy - TMS-related contraindications (pacemaker, metallic implant) - History of chronic headache (>15 days/month for 3 months) or migraine prior to most recent trauma - Other medical conditions such as: structural brain disease, previous seizure, psychotic disorders (schizophrenia, bipolar disorder), liver or kidney disease, malignancy, uncontrolled hypertension or diabetes, and pregnancy | ||
性别 |
|
||
年龄 | 最小年龄:16 Years ,最大年龄:65 Years | ||
接受健康的志愿者 | 没有 | ||
可入组国家 ICMJE | Canada | ||
管理信息 | 数据检测委员会 | Yes | |
研究涉及美国FDA监管的产品 |
研究美国FDA监管的药品: No 研究涉及美国FDA监管的设备产品: No |
||
IPD 共享声明 |
|
||
责任方 | , | ||
研究赞助商 ICMJE | University of Calgary | ||
合作者 ICMJE | |||
研究员 ICMJE |
|
||
PRS 账户 | |||
验证日期 | September 2018 | ||
ICMJE 国际医学期刊编辑委员会和 世界卫生组织 ICTRP 要求的元素 |